A detailed history of Ubs Group Ag transactions in Entera Bio Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 167,623 shares of ENTX stock, worth $336,922. This represents 0.0% of its overall portfolio holdings.

Number of Shares
167,623
Previous 149,869 11.85%
Holding current value
$336,922
Previous $250,000 23.2%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.73 - $2.98 $30,714 - $52,906
17,754 Added 11.85%
167,623 $308,000
Q1 2024

May 13, 2024

BUY
$0.64 - $1.72 $95,916 - $257,774
149,869 New
149,869 $250,000
Q3 2023

Nov 09, 2023

SELL
$0.6 - $0.88 $270 - $396
-450 Reduced 42.29%
614 $0
Q2 2023

Aug 11, 2023

SELL
$0.68 - $1.01 $5,899 - $8,762
-8,676 Reduced 89.08%
1,064 $0
Q1 2023

May 12, 2023

SELL
$0.83 - $1.44 $537 - $933
-648 Reduced 6.24%
9,740 $11,000
Q4 2022

Feb 08, 2023

BUY
$0.5 - $1.05 $4,317 - $9,065
8,634 Added 492.25%
10,388 $7,000
Q3 2022

Nov 10, 2022

SELL
$0.07 - $1.98 $395 - $11,187
-5,650 Reduced 76.31%
1,754 $2,000
Q2 2022

Aug 10, 2022

BUY
$1.33 - $2.95 $3,649 - $8,094
2,744 Added 58.88%
7,404 $10,000
Q1 2022

May 16, 2022

BUY
$1.91 - $3.23 $8,900 - $15,051
4,660 New
4,660 $13,000
Q4 2021

Feb 14, 2022

SELL
$2.82 - $4.79 $1,593 - $2,706
-565 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$4.43 - $6.29 $2,024 - $2,874
-457 Reduced 44.72%
565 $3,000
Q2 2021

Aug 13, 2021

SELL
$2.92 - $6.5 $1,728 - $3,848
-592 Reduced 36.68%
1,022 $6,000
Q1 2021

May 12, 2021

BUY
$1.16 - $6.9 $1,327 - $7,893
1,144 Added 243.4%
1,614 $6,000
Q4 2020

Feb 11, 2021

SELL
$1.03 - $1.24 $7,589 - $9,136
-7,368 Reduced 94.0%
470 $1,000
Q3 2020

Nov 12, 2020

SELL
$1.05 - $2.2 $2,671 - $5,596
-2,544 Reduced 24.5%
7,838 $10,000
Q2 2020

Jul 31, 2020

BUY
$1.71 - $3.01 $17,753 - $31,249
10,382 New
10,382 $19,000
Q1 2020

May 01, 2020

SELL
$1.6 - $3.34 $992 - $2,070
-620 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.84 - $2.97 $285 - $460
155 Added 33.33%
620 $1,000
Q3 2019

Nov 14, 2019

SELL
$2.11 - $3.75 $468 - $832
-222 Reduced 32.31%
465 $1,000
Q2 2019

Aug 14, 2019

SELL
$2.92 - $4.4 $1,314 - $1,980
-450 Reduced 39.58%
687 $2,000
Q1 2019

May 14, 2019

BUY
$3.01 - $4.84 $3,422 - $5,503
1,137 New
1,137 $5,000
Q4 2018

Feb 14, 2019

SELL
$3.0 - $5.85 $1,095 - $2,135
-365 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$4.5 - $6.7 $4,833 - $7,195
-1,074 Reduced 74.64%
365 $2,000
Q2 2018

Aug 14, 2018

BUY
$6.28 - $6.3 $9,036 - $9,065
1,439 New
1,439 $9,000

Others Institutions Holding ENTX

About Entera Bio Ltd.


  • Ticker ENTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,809,900
  • Market Cap $57.9M
  • Description
  • Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...
More about ENTX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.